INCY vs TECH — Key Metrics
| Metric | INCY (INCYTE CORP) | TECH (BIO-TECHNE CORP) |
|---|---|---|
| Price | 117.8 | 72.75 |
| Market Cap | 24.01 Billion | 11.43 Billion |
| P/E (TTM) | 56.36 | 66.14 |
| P/B (Quarterly) | 4.219 | 5.284 |
| P/S (TTM) | 3.99 | 9.3 |
| Net Profit Margin (TTM) | 6.7 | 14.0 |
| Gross Margin (TTM) | 92.7 | 65.8 |
| ROE (TTM) | 7.1 | 8.2 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Greatly Outperform
Underperform
Recommendation Summary
Stock INCY is projected to greatly outperform the market, stock TECH is projected to underperform the market. Upfront Recommendation: INCY.
Financial Metrics
| INCY | Metrics | TECH |
|---|---|---|
| $117.80 | Price | $72.75 |
| — | Market Capitalization | — |
| 56.36 | Price to Earnings Ratio | 66.14 |
| 3.99 | Price to Sales | 9.3 |
| 35.06 | Price to FCF Ratio | 37.08 |
| 4.31 | Price to Gross Profit | 14.15 |
| 6.99 | Price to R&D | 117.98 |
| 4.35 | Price to Current Assets | 13.86 |
INCY vs TECH at a glance
Incyte Corp (INCY) and Bio-techne Corp (TECH) are both Biotechnology companies in the Healthcare sector. INCY is the larger, at $24.0 billion in market value against $11.4 billion for TECH, about 2.1 times the size.
On trailing-twelve-month figures, INCY trades at 56.4 times trailing earnings and TECH at 66.1; net profit margins are 6.7% and 14.0%.
The Upfront Investment model currently rates INCY Greatly Outperform and TECH Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.